While it develops a comprehensive scorecard for assetssing cancer drugs on the basis of benefit, toxicity and cost, the American Society of Clinical Oncology has put a stake in the ground for what constitutes a meaningful benefit in advanced pancreatic, lung, breast and colon cancers. ASCO is proposing